440 related articles for article (PubMed ID: 21394667)
1. Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.
Kikuchi H; Setoguchi T; Miyazaki S; Yamamoto M; Ohta M; Kamiya K; Sakaguchi T; Konno H
Int J Clin Oncol; 2011 Dec; 16(6):741-5. PubMed ID: 21394667
[TBL] [Abstract][Full Text] [Related]
2. Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.
Gao J; Tian Y; Li J; Sun N; Yuan J; Shen L
Med Oncol; 2013 Jun; 30(2):522. PubMed ID: 23456621
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.
Li J; Gao J; Hong J; Shen L
Future Oncol; 2012 May; 8(5):617-24. PubMed ID: 22646775
[TBL] [Abstract][Full Text] [Related]
4. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis and management of gastrointestinal stromal tumors.
Bayraktar UD; Bayraktar S; Rocha-Lima CM
World J Gastroenterol; 2010 Jun; 16(22):2726-34. PubMed ID: 20533592
[TBL] [Abstract][Full Text] [Related]
6. Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.
Zhao J; Quan H; Xu Y; Kong X; Jin L; Lou L
Cancer Sci; 2014 Jan; 105(1):117-25. PubMed ID: 24205792
[TBL] [Abstract][Full Text] [Related]
7. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal stromal tumors: imatinib and beyond.
Schnadig ID; Blanke CD
Curr Treat Options Oncol; 2006 Nov; 7(6):427-37. PubMed ID: 17032555
[TBL] [Abstract][Full Text] [Related]
9. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
[TBL] [Abstract][Full Text] [Related]
10. [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Italiano A; Bui B
Bull Cancer; 2008 Jan; 95(1):107-16. PubMed ID: 18230576
[TBL] [Abstract][Full Text] [Related]
11. Rapid relapse after resection of a sunitinib-resistant gastrointestinal stromal tumor harboring a secondary mutation in exon 13 of the c-KIT gene.
Kikuchi H; Miyazaki S; Setoguchi T; Hiramatsu Y; Ohta M; Kamiya K; Sakaguchi T; Konno H
Anticancer Res; 2012 Sep; 32(9):4105-9. PubMed ID: 22993368
[TBL] [Abstract][Full Text] [Related]
12. Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.
Sjölund K; Andersson A; Nilsson E; Nilsson O; Ahlman H; Nilsson B
World J Surg; 2010 Sep; 34(9):2090-7. PubMed ID: 20512492
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.
Yoon DH; Ryu MH; Ryoo BY; Beck M; Choi DR; Cho Y; Lee JL; Chang HM; Kim TW; Kang YK
Invest New Drugs; 2012 Apr; 30(2):819-27. PubMed ID: 21104107
[TBL] [Abstract][Full Text] [Related]
14. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
15. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
Hong JL; Li J; Li J; Shen L
Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
Liegl B; Kepten I; Le C; Zhu M; Demetri GD; Heinrich MC; Fletcher CD; Corless CL; Fletcher JA
J Pathol; 2008 Sep; 216(1):64-74. PubMed ID: 18623623
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
18. Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib?
Pantaleo MA; Di Battista M; Catena F; Astorino M; Saponara M; Di Scioscio V; Santini D; Piazzi G; Castellucci P; Brandi G; Biasco G
J Cancer Res Clin Oncol; 2008 May; 134(5):625-30. PubMed ID: 18202855
[TBL] [Abstract][Full Text] [Related]
19. Developments in targeted therapy of advanced gastrointestinal stromal tumors.
Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751
[TBL] [Abstract][Full Text] [Related]
20. [Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors].
Zheng S; Jia J; Pan YL; Tao DY; Lu HS
Zhonghua Bing Li Xue Za Zhi; 2013 Jan; 42(1):42-3. PubMed ID: 23611272
[No Abstract] [Full Text] [Related]
[Next] [New Search]
